Showing 1–2 of 2 results for author: Ceccarelli, M

TEX (TEst stand for X-band) at LNF

Authors: C. Di Giulio, F. Cardelli, S. Pioli, D. Alesini, M. Bellaveglia, S. Bini, B. Buonomo, S. Cantarella, G. Catuscelli, M. Ceccarelli, R. Ceccarelli, M. Cianfrini, R. Clementi, E. Di Pasquale, G. Di Raddo, R. Di Raddo, A. Falone, A. Gallo, G. Latini, A. Liedl, V. Lollo, G. Piermarini, L. Piersanti, S. Quaglia, L. A. Rossi , et al. (5 additional authors not shown)

Abstract: TEX facility if commissioned for high power testing to characterize accelerating structures and validate them for the operation on future particle accelerators for medical, industrial and research applications. At this aim, TEX is directly involved in the LNF leading project EuPRAXIA@SPARC_Lab. The brief description of the facility and its status and prospective will be provided. TEX facility if commissioned for high power testing to characterize accelerating structures and validate them for the operation on future particle accelerators for medical, industrial and research applications. At this aim, TEX is directly involved in the LNF leading project EuPRAXIA@SPARC_Lab. The brief description of the facility and its status and prospective will be provided. △ Less

Submitted 31 August, 2023; v1 submitted 6 August, 2023; originally announced August 2023.

Comments: Talk presented at the International Workshop on Future Linear Colliders (LCWS 2023), 15-19 May 2023. C23-05-15.3

$^7$Be and $^{22}$Na radionuclides for a new therapy of cancer

Authors: V. I. Kukulin, A. V. Bibikov, E. V. Tkalya, M. Ceccarelli, I. V. Bodrenko

Abstract: The $^{10}$B isotope has been almost exclusively used in the neutron-capture radiation therapy (NCT) of cancer for decades. We have identified two other nuclides suitable for the radiotherapy, which have ca.10 times larger cross section of absorption for neutrons and emit heavy charged particles. This would provide several key advantages for potential NCT, such as the possibility to use either a l… ▽ More The $^{10}$B isotope has been almost exclusively used in the neutron-capture radiation therapy (NCT) of cancer for decades. We have identified two other nuclides suitable for the radiotherapy, which have ca.10 times larger cross section of absorption for neutrons and emit heavy charged particles. This would provide several key advantages for potential NCT, such as the possibility to use either a lower nuclide concentration in the target tissues, or a lower neutron irradiation flux. By detecting the characteristic $γ$ radiation from the spontaneous decay of the radionuclides, one can image and control their accumulation. These advantages could be critical for the revival of the NCT as a safer, more efficient and more widely used cancer therapy. △ Less

Submitted 12 July, 2019; originally announced July 2019.